Articles from Phibro Animal Health Corporation

The Board of Directors of Phibro Animal Health Corporation (Nasdaq: PAHC) today announced the appointment of Joyce J. Lee, MBA, as a Class II director of the Company, effective immediately. Ms. Lee will be an independent director. Her appointment fills a current vacancy and increases Board membership to nine directors, 6 of whom are independent directors.

Phibro Animal Health Corporation (Nasdaq: PAHC) expects to announce its second quarter financial results on Wednesday, February 5, 2025, after the market closes. Phibro management will host a conference call and webcast on Thursday, February 6, 2025, at 9:00 AM Eastern Time.

Phibro Animal Health Corporation (Nasdaq: PAHC) (“Phibro” or the “Company”) today announced financial results for its first quarter ended September 30, 2024, and its updated financial guidance for the year ending June 30, 2025.

The Board of Directors of Phibro Animal Health Corporation (Nasdaq: PAHC) today declared a quarterly cash dividend of $0.12 per share on its Class A common stock and Class B common stock, payable on December 18, 2024, to stockholders of record at the close of business on November 27, 2024.

Phibro Animal Health Corporation (Nasdaq: PAHC) today announced the successful completion of the acquisition of the medicated feed additive product portfolio and certain water-soluble products from Zoetis Inc. (NYSEZTS). This acquisition marks a significant step in furthering Phibro’s purpose to optimize global animal health and nutrition for better lives and a more sustainable world.

Phibro Animal Health Corporation (Nasdaq: PAHC) expects to announce its first quarter financial results on Wednesday, November 6, 2024, after the market closes. Phibro management will host a conference call and webcast on Thursday, November 7, 2024, at 9:00 AM Eastern Time.

Phibro Animal Health Corporation (Nasdaq: PAHC) announced today it will participate in the Morgan Stanley Annual Global Healthcare Conference.

Phibro Animal Health Corporation (Nasdaq: PAHC) (“Phibro” or the “Company”) today announced financial results for its fourth quarter and fiscal year ended June 30, 2024 and provided its financial guidance for the year ending June 30, 2025.

Phibro Animal Health Corporation (Nasdaq: PAHC) expects to announce its fourth quarter and fiscal year 2024 financial results on Wednesday, August 28, 2024, after the market closes. Phibro management will host a conference call and webcast on Thursday, August 29, 2024, at 9:00 AM Eastern Time.

The Board of Directors of Phibro Animal Health Corporation (Nasdaq: PAHC) today declared a quarterly cash dividend of $0.12 per share on its Class A common stock and Class B common stock, payable on September 25, 2024, to stockholders of record at the close of business on September 4, 2024.

Phibro Animal Health Corporation (Nasdaq: PAHC) proudly announces its third annual Environmental, Social and Governance (ESG) Report, highlighting 2023 achievements. At Phibro, the connections between people, animals and the planet drive us to optimize animal health and nutrition for better lives and a sustainable world.

Phibro Animal Health Corporation (Nasdaq: PAHC) announced today it will participate in the Stifel Annual Dental and Animal Health (Jaws & Paws) Conference.

Phibro Animal Health Corporation (Nasdaq: PAHC) (“Phibro” or the “Company”) today announced financial results for its third quarter ended March 31, 2024, and its updated financial guidance for the year ending June 30, 2024.

The Board of Directors of Phibro Animal Health Corporation (Nasdaq:PAHC) today declared a quarterly cash dividend of $0.12 per share on its Class A common stock and Class B common stock, payable on June 26, 2024, to stockholders of record at the close of business on June 5, 2024.

Phibro Animal Health Corporation (Nasdaq: PAHC) expects to announce its third quarter financial results on Wednesday, May 8, 2024, after the market closes. Phibro management will host a conference call and webcast on Thursday, May 9, 2024, at 9:00 AM Eastern Time.

Phibro Animal Health Corporation (Nasdaq: PAHC) announced today it will participate in the Barclays Global Healthcare Conference.

Phibro Animal Health Corporation (Nasdaq: PAHC) announced today it will participate in the Bank of America 2024 Virtual Animal Health Summit.

Phibro Animal Health Corporation (Nasdaq: PAHC) (“Phibro” or the “Company”) today announced financial results for its second quarter ended December 31, 2023 and its updated financial guidance for the year ending June 30, 2024.

The Board of Directors of Phibro Animal Health Corporation (Nasdaq: PAHC) today declared a quarterly cash dividend of $0.12 per share on its Class A common stock and Class B common stock, payable on March 27, 2024, to stockholders of record at the close of business on March 6, 2024.

Phibro Animal Health Corporation (Nasdaq: PAHC) (the “Company” or “Phibro”) today announced that Glenn C. David has joined Phibro and will assume the role of Chief Financial Officer effective February 9, 2024. Mr. Richard Johnson, who is currently serving as Phibro’s interim Chief Financial Officer since September 29, 2023, will continue with Phibro for a period of time in an advisory capacity to ensure a smooth transition with his successor.

Phibro Animal Health Corporation (Nasdaq: PAHC) expects to announce its second quarter financial results on Wednesday, February 7, 2024, after the market closes. Phibro management will host a conference call and webcast on Thursday, February 8, 2024, at 9:00 AM Eastern Time.

Phibro Animal Health Corporation (Nasdaq: PAHC) (“Phibro” or the “Company”) today announced financial results for its first quarter ended September 30, 2023, and its updated financial guidance for the year ending June 30, 2024.

(NASDAQPAHC) The Food and Drug Administration (FDA), through its Center for Veterinary Medicine (CVM), has taken two actions regarding Mecadox® (carbadox), a drug marketed by Phibro Animal Health Corporation.

The Board of Directors of Phibro Animal Health Corporation (Nasdaq:PAHC) today declared a quarterly cash dividend of $0.12 per share on its Class A common stock and Class B common stock, payable on December 20, 2023, to stockholders of record at the close of business on November 29, 2023.

Phibro Animal Health Corporation (Nasdaq: PAHC) expects to announce its first quarter financial results on Wednesday, November 8, 2023, after the market closes. Phibro management will host a conference call and webcast on Thursday, November 9, 2023, at 9:00 AM Eastern Time.

Phibro Animal Health Corporation (Nasdaq:PAHC) (“Phibro” or the “Company”) today announced that Damian Finio, Phibro’s Chief Financial Officer, has informed the Company that he will resign from his position effective September 29, 2023.

Phibro Animal Health Corporation (Nasdaq: PAHC) (“Phibro” or the “Company”) today announced financial results for its fourth quarter and fiscal year ended June 30, 2023, and provided guidance for the year ending June 30, 2024.

Phibro Animal Health Corporation (Nasdaq: PAHC) expects to announce its fourth quarter and fiscal year 2023 financial results on Wednesday, August 30, 2023, after the market closes. Phibro management will host a conference call and webcast on Thursday, August 31, 2023, at 9:00 AM Eastern Time.

The Board of Directors of Phibro Animal Health Corporation (Nasdaq: PAHC) today declared a quarterly cash dividend of $0.12 per share on its Class A common stock and Class B common stock, payable on September 27, 2023, to stockholders of record at the close of business on September 6, 2023.

Phibro Animal Health Corporation (Nasdaq: PAHC) is a global leader in animal health and mineral nutrition. We partner with livestock producers, farmers, veterinarians, and consumers who raise or care for farm and companion animals. We provide solutions to help them maintain and enhance the health of their animals.

Phibro Animal Health Corporation (Nasdaq: PAHC) (“Phibro” or the “Company”) today announced financial results for its third quarter and year-to-date ended March 31, 2023.

The Board of Directors of Phibro Animal Health Corporation (Nasdaq: PAHC) today declared a quarterly cash dividend of $0.12 per share on its Class A common stock and Class B common stock, payable on June 28, 2023, to stockholders of record at the close of business on June 7, 2023.

Phibro Animal Health Corporation (Nasdaq: PAHC) expects to announce its third quarter financial results on Wednesday, May 3, 2023, after the market closes. Phibro management will host a conference call and webcast on Thursday, May 4, 2023, at 9:00 AM Eastern Time.

Phibro Animal Health Corporation (Nasdaq: PAHC) announced today it will participate in the Bank of America Securities 2023 Health Care Conference.

Phibro Animal Health Corporation (Nasdaq: PAHC) announced today it will participate in the Barclays Global Healthcare Conference.

Phibro Animal Health Corporation (Nasdaq:PAHC) announced today it will participate in the Bank of America 2023 Virtual Animal Health Summit.

Phibro Animal Health Corporation (Nasdaq: PAHC) (“Phibro” or the “Company”) today announced financial results for its second quarter ended December 31, 2022.

The Board of Directors of Phibro Animal Health Corporation (Nasdaq: PAHC) today announced the appointment of Alejandro Bernal, DVM, MS, MBA, as a Class III director of the Company, effective immediately. Mr. Bernal will be an independent director. His appointment fills a current vacancy and increases Board membership to nine directors, 6 of whom are independent directors.

Phibro Animal Health Corporation (Nasdaq:PAHC) expects to announce its second quarter financial results on Wednesday, February 8, 2023, after the market closes. Phibro management will host a conference call and webcast on Thursday, February 9, 2023, at 9:00 AM Eastern Time.

Phibro Animal Health Corporation (Nasdaq: PAHC) (“Phibro” or the “Company”) today announced financial results for its first quarter ended September 30, 2022, and reiterated its financial guidance for Net sales and Adjusted EBITDA and revised its guidance for Net income, Diluted EPS, Adjusted net income, Adjusted diluted EPS and Adjusted effective tax rate for the year ending June 30, 2023.

The Board of Directors of Phibro Animal Health Corporation (Nasdaq:PAHC) today declared a quarterly cash dividend of $0.12 per share on its Class A common stock and Class B common stock, payable on December 21, 2022, to stockholders of record at the close of business on November 30, 2022.

Phibro Animal Health Corporation (Nasdaq:PAHC) expects to announce its first quarter financial results on Wednesday, November 9, 2022, after the market closes. Phibro management will host a conference call and webcast on Thursday, November 10, 2022, at 9:00 AM Eastern Time.

Phibro Animal Health Corporation (Nasdaq:PAHC) (“Phibro” or the “Company”) today announced financial results for its fourth quarter and fiscal year ended June 30, 2022, and provided financial guidance for the year ending June 30, 2023.

Phibro Animal Health Corporation (Nasdaq:PAHC) announced today it will participate in the Morgan Stanley Global Healthcare Conference being held at the Sheraton New York.

Phibro Animal Health Corporation (Nasdaq:PAHC) expects to announce its fourth quarter and fiscal year 2022 financial results on Wednesday, August 24, 2022, after the market closes. Phibro management will host a conference call and webcast on Thursday, August 25, 2022, at 9:00 AM Eastern Time.

The Board of Directors of Phibro Animal Health Corporation (Nasdaq:PAHC) today declared a quarterly cash dividend of $0.12 per share on its Class A common stock and Class B common stock, payable on September 28, 2022, to stockholders of record at the close of business on September 7, 2022.

Phibro Animal Health Corporation (Nasdaq:PAHC) and Rejuvenate Bio, Inc. today announced a collaboration for the development and commercialization of a gene therapy for Mitral Valve Disease (MVD) in canines (dogs).

Phibro Animal Health Corporation (Nasdaq: PAHC), a diversified global developer, manufacturer, and supplier of a broad range of animal health and mineral nutrition products for livestock, published its inaugural Environmental, Social and Governance (ESG) Report (the “Report”). The Report establishes Phibro’s baseline on certain key performance indicators as of December 31, 2021, by providing disclosures containing relevant, industry-specific data and information aligned with the Sustainability Accounting Standards Board (SASB) framework, along with select disclosures aligned with the Global Reporting Initiative (GRI) framework. In addition, the Report captures the myriad ways Phibro empowers its people, protects the environment, acts with integrity, and engages with the communities in which it operates globally.

Phibro Animal Health Corporation (Nasdaq: PAHC) today announced financial results for its third quarter ended March 31, 2022.

The Board of Directors of Phibro Animal Health Corporation (Nasdaq:PAHC) today declared a quarterly cash dividend of $0.12 per share on its Class A common stock and Class B common stock, payable on June 22, 2022, to stockholders of record at the close of business on June 1, 2022.

Phibro Animal Health Corporation (Nasdaq:PAHC) expects to announce its third quarter financial results on Wednesday, May 4, 2022, after the market closes. Phibro management will host a conference call and webcast on Thursday, May 5, 2022, at 9:00 AM Eastern Time.

Phibro Animal Health Corporation (NASDAQPAHC) announced today that it will participate in the Barclays Global Healthcare Conference being held at the Loews Miami Beach Hotel in Miami Beach, Florida.

Phibro Animal Health Corporation (Nasdaq:PAHC) today announced financial results for its second quarter ended December 31, 2021.

The Board of Directors of Phibro Animal Health Corporation (Nasdaq:PAHC) today declared a quarterly cash dividend of $0.12 per share on its Class A common stock and Class B common stock, payable on March 23, 2022, to stockholders of record at the close of business on March 2, 2022.

Phibro Animal Health Corporation (NASDAQPAHC) announced today that it will participate in the BofA Securities 2022 Virtual Animal Health Summit.

Phibro Animal Health Corporation (NASDAQPAHC): Today, the Food and Drug Administration (FDA) provided notice in the Federal Register of its intention to hold a public hearing regarding Mecadox® (carbadox). Mecadox has been approved and sold in the United States for 50 years and is a widely used treatment for controlling bacterial diseases in swine, including Salmonella and swine dysentery, resulting in improved health and welfare for newly born and young pigs.

Phibro Animal Health Corporation (Nasdaq:PAHC) expects to announce its second quarter financial results on Wednesday, February 9, 2022, after the market closes. Phibro management will host a conference call and webcast on Thursday, February 10, 2022, at 9:00 AM Eastern Time.

Phibro Animal Health Corporation (NASDAQPAHC) announced today that it will participate in the 4th Annual Evercore ISI Virtual Conference.

Phibro Animal Health Corporation (Nasdaq:PAHC) today announced financial results for its first quarter ended September 30, 2021.

The Board of Directors of Phibro Animal Health Corporation (Nasdaq:PAHC) today declared a quarterly cash dividend of $0.12 per share on its Class A common stock and Class B common stock, payable on December 15, 2021, to stockholders of record at the close of business on November 24, 2021.

Phibro Animal Health Corporation (Nasdaq:PAHC) expects to announce its first quarter financial results on Tuesday, November 2, 2021, after the market closes. Phibro management will host a conference call and webcast on Wednesday, November 3, 2021, at 9:00 AM Eastern Time.

Phibro Animal Health Corporation (NASDAQPAHC) announced today it will participate in the 30th Annual Credit Suisse Virtual Healthcare Conference.

Phibro Animal Health Corporation (Nasdaq:PAHC) today announced financial results for its fourth quarter and fiscal year ended June 30, 2021, and provided financial guidance for the year ending June 30, 2022.

Phibro Animal Health Corporation (Nasdaq:PAHC) announced today it will participate in the Morgan Stanley Virtual Global Healthcare Conference.

Phibro Animal Health Corporation (Nasdaq:PAHC) announced today it will participate in the Bank of America Virtual Global Healthcare Conference.

Phibro Animal Health Corporation (Nasdaq:PAHC) expects to announce its fourth quarter and fiscal year 2021 financial results on Wednesday, August 25, 2021, after the market closes. Phibro management will host a conference call and webcast on Thursday, August 26, 2021, at 9:00 AM Eastern Time.

The Board of Directors of Phibro Animal Health Corporation (Nasdaq:PAHC) today declared a quarterly cash dividend of $0.12 per share on its Class A common stock and Class B common stock, payable on September 22, 2021, to stockholders of record at the close of business on September 1, 2021.

Phibro Animal Health Corporation (NASDAQPAHC) today announced financial results for its third quarter and year-to-date period ended March 31, 2021.

The Board of Directors of Phibro Animal Health Corporation (Nasdaq:PAHC) today declared a quarterly cash dividend of $0.12 per share on its Class A common stock and Class B common stock, payable on June 23, 2021, to stockholders of record at the close of business on June 2, 2021.

Phibro Animal Health Corporation (NASDAQPAHC) announced today that on April 22, 2021, the Company entered into an amended and restated credit agreement. Under the amended and restated credit agreement, the lenders agreed to extend credit to the Company in the form of Term A loans in an aggregate principal amount of $300 million (“Term A Loans”) and a revolving credit facility in an aggregate principal amount of $250 million (“Revolver”).

Phibro Animal Health Corporation (NASDAQPAHC) expects to announce its third quarter financial results on Thursday, May 6, 2021, after the market closes. Phibro management will host a conference call and webcast on Friday, May 7, 2021 at 9:00 AM Eastern Time.

Phibro Animal Health Corporation (NASDAQPAHC) announced today it will participate in the Bank of America Securities 2021 Virtual Healthcare Conference.